Publications for Gregory Fulcher
2016
Fulcher, G., Christiansen, J., Bantwal, G.,
Polaszewska-Muszyiska, M., Mersebach, H.,
Andersen, T., Niskanen, L. (2016). Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulintreated type 2 diabetes: A phase 3a, randomized, treat-to-target trial. Diabetes Technology and
Therapeutics , 18, 49-50. <a href="http://dx.doi.org/10.1089/dia.2016.2505">
[More Information]</a>
Fulcher, G., Matthews, D., Perkovic, V., de
Zeeuw, D., Mahaffey, K., Mathieu, C., Woo, V.,
Wysham, C., Capuano, G., Desai, M., Neal, B., et al (2016). Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.
Diabetes, Obesity and Metabolism , 18(1), 82-91.
<a href="http://dx.doi.org/10.1111/dom.12589">[M ore Information]</a>
McGrath, R., Donnelly, V., Glastras, S., Preda,
V., Sheriff, N., Ward, P., Hocking, S., Fulcher,
G. (2016). Evaluation of Blood Glucose Meter
Efficacy in an Antenatal Diabetes Clinic.
Diabetes Technology and Therapeutics , 18(2),
68-74. <a href="http://dx.doi.org/10.1089/dia.2015.0104">
[More Information]</a>
McGrath, R., Hocking, S., Priglinger, M., Day,
S., Herkes, G., Krause, M., Fulcher, G. (2016).
Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study.
BMJ Open , 6(2), 1-7. <a href="http://dx.doi.org/10.1136/bmjopen-2015-0
08203">[More Information]</a>
2015
McGrath, R., Glastras, S., Hocking, S., Tjoeng,
I., Krause, M., Fulcher, G. (2015). Central
Functions of Glucagon-like Peptide-1: Roles in
Energy Regulation and Neuroprotection. Journal of Steroids & Hormonal Science , 6(1), 1-8. <a href="http://dx.doi.org/10.4172/2157-7536.1000.
152">[More Information]</a>
Fulcher, G., Matthews, D., Perkovic, V., de
Zeeuw, D., Mahaffey, K., Weiss, R., Rosenstock,
J., Capuano, G., Desai, M., Shaw, W., Neal, B., et al (2015). Efficacy and Safety of Canagliflozin
Used in Conjunction with Sulfonylurea in
Patients with Type 2 Diabetes Mellitus: A
Randomized, Controlled Trial. Diabetes
Therapy , 6(3), 289-302. <a href="http://dx.doi.org/10.1007/s13300-015-011
7-z">[More Information]</a>
Publications for Gregory Fulcher
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey,
K., Fulcher, G., Ways, K., Desai, M., Shaw, W.,
Capuano, G., Alba, M., et al (2015). Efficacy and
Safety of Canagliflozin, an Inhibitor of Sodium
Glucose Cotransporter 2, When Used in
Conjunction With Insulin Therapy in Patients
With Type 2 Diabetes. Diabetes Care , 38(3),
403-411. <a href="http://dx.doi.org/10.2337/dc14-1237">[M ore Information]</a>
Xu, S., Alexander, K., Bryant, W., Cohen, N.,
Craig, M., Forbes, M., Fulcher, G., Greenaway,
T., Harrison, N., Holmes-Walker, J., Jenkins, A., et al (2015). Healthcare professional requirements for the care of adult diabetes patients managed with insulin pumps in
Australia. Internal Medicine Journal , 45(1),
86-93. <a href="http://dx.doi.org/10.1111/imj.12619">[Mo re Information]</a>
Atkin, S., Javed, Z., Fulcher, G. (2015). Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus.
Therapeutic Advances in Chronic Diseases , 6(6),
375-388. <a href="http://dx.doi.org/10.1177/2040622315608
646">[More Information]</a>
Clifton-Bligh, P., Nery, L., Supramaniam, R.,
Reeve, T., Delbridge, L., Stiel, J., McElduff, A.,
Wilmshurst, E., Robinson, B., Fulcher, G.,
Learoyd, D., Posen, S. (2015). Mortality associated with primary hyperparathyroidism.
Bone , 74, 121-124. <a href="http://dx.doi.org/10.1016/j.bone.2014.12.0
67">[More Information]</a>
Wu, T., Betty, B., Downie, M., Khanolkar, M.,
Kilov, G., Orr-Walker, B., Senator, G., Fulcher,
G. (2015). Practical Guidance on the Use of
Premix Insulin Analogs in Initiating,
Intensifying, or Switching Insulin Regimens in
Type 2 Diabetes. Diabetes Therapy , 6(3),
273-287. <a href="http://dx.doi.org/10.1007/s13300-015-011
6-0">[More Information]</a>
Clifton-Bligh, P., Nery,, M., Clifton-Bligh, R.,
Visvalingam, S., Fulcher, G., Byth Wilson, K.,
Baber, R. (2015). Red clover isoflavones enriched with formononetin lower serum LDL cholesterol-a randomized, double-blind, placebo-controlled study. European Journal of
Clinical Nutrition , 69(1), 134-142. <a href="http://dx.doi.org/10.1038/ejcn.2014.207">
[More Information]</a>
Whitmont, K., McKelvey, K., Fulcher, G., Reid,
I., March, L., Xue, M., Cooper, A., Jackson, C.
(2015). Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo-controlled, double-blind pilot clinical

trial. International Wound Journal , 12(4),
422-427. <a href="http://dx.doi.org/10.1111/iwj.12125">[Mo re Information]</a>
Fulcher, G., Roberts, A., Sinha, A., Proietto, J.
(2015). What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres. Diabetes Research and Clinical
Practice , 108(3), 405-413. <a href="http://dx.doi.org/10.1016/j.diabres.2015.03
.004">[More Information]</a>
2014
Fulcher, G., Christiansen, J., Bantwal, G.,
Polaszewska-Muszynska, M., Mersebach, H.,
Andersen, T., Niskanen, L. (2014). Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: A phase 3a, randomized, treat-to-target trial. Diabetes Care , 37(8),
2084-2090. <a href="http://dx.doi.org/10.2337/dc13-2908">[M ore Information]</a>
Van Dieren, S., Kengne, A., Chalmers, J.,
Beulens, J., Davis, T., Fulcher, G., Heller, S.,
Patel, A., Colagiuri, S., Hamet, P., Neal, B.,
Woodward, M., Zoungas, S., et al (2014).
Intensification of medication and glycaemic control among patients with type 2 diabetes - the
ADVANCE trial. Diabetes, Obesity and
Metabolism , 16(5), 426-432. <a href="http://dx.doi.org/10.1111/dom.12238">[M ore Information]</a>
Fulcher, G., Singer, J., Castaneda, R., Filho, F.,
Maffei, L., Snyman, J., Brod, M. (2014). The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys. Journal of Medical
Economics , 17(10), 751-761. <a href="http://dx.doi.org/10.3111/13696998.2014.
946992">[More Information]</a>
Kapila, S., Reid, I., Dixit, S., Fulcher, G., March,
L., Jackson, C., Cooper, A. (2014). Use of dermal injection of activated protein C for treatment of large chronic wounds secondary to pyoderma gangrenosum. Clinical and
Experimental Dermatology , 39(7), 785-790. <a href="http://dx.doi.org/10.1111/ced.12361">[Mo re Information]</a>
2013
Bethel, M., Chacra, A., Deedwania, P., Fulcher,
G., Holman, R., Jenssen, T., Kahn, S., Levitt, N.,
McMurray, J., Califf, R., et al (2013). A Novel
Risk Classification Paradigm for Patients With
Impaired Glucose Tolerance and High
Cardiovascular Risk. The American Journal of
Publications for Gregory Fulcher
Cardiology , 112(2), 231-237. <a href="http://dx.doi.org/10.1016/j.amjcard.2013.0
3.019">[More Information]</a>
Hata, J., Arima, H., Zoungas, S., Fulcher, G.,
Pollock, C., Adams, M., Watson, J., Joshi, R.,
Kengne, A., Ninomiya, T., Anderson, C.,
Woodward, M., Patel, A., MacMahon, S.,
Chalmers, J., Neal, B., et al (2013). Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial.
PloS One , 8(2), 1-7. <a href="http://dx.doi.org/10.1371/journal.pone.005
5807">[More Information]</a>
Whitmont, K., Fulcher, G., Reid, I., Xue, M.,
McKelvey, K., Xie, Y., Aboud, M., Ward, C.,
Smith, M., Cooper, A., March, L., Jackson, C.
(2013). Low Circulating Protein C Levels Are
Associated with Lower Leg Ulcers in Patients with Diabetes. BioMed Research International ,
2013, 1-4. <a href="http://dx.doi.org/10.1155/2013/719570">[
More Information]</a>
Alexander, K., Bryant, W., Cohen, N., Craig, M.,
Forbes, M., Fulcher, G., Greenaway, T.,
Harrison, N., Holmes-Walker, J., Howard, G.,
Jenkins, A., et al (2013). Provision of Quality
Care for Adults with Type 1 Diabetes Requiring
Insulin Pump Therapy (IIPT). Infusystems Asia ,
8(1), 1-6.
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey,
K., Fulcher, G., Stein, P., Desai, M., Shaw, W.,
Jiang, J., Vercruysse, F., et al (2013). Rationale, design, and baseline characteristics of the
Canagliflozin Cardiovascular Assessment Study
(CANVAS)-A randomized placebo-controlled trial. American Heart Journal , 166(2), 217-223.
<a href="http://dx.doi.org/10.1016/j.ahj.2013.05.00
7">[More Information]</a>
2012
Xue, M., Dervish, S., Harrison, L., Fulcher, G.,
Jackson, C. (2012). Activated protein C inhibits pancreatic islet inflammation, stimulates T regulatory cells, and prevents diabetes in non-obese diabetic (NOD) mice. Journal of
Biological Chemistry , 287(20), 16356-16364. <a href="http://dx.doi.org/10.1074/jbc.M111.32595
1">[More Information]</a>
Zoungas, S., Chalmers, J., Ninomiya, T., Li, Q.,
Cooper, M., Colagiuri, S., Fulcher, G., de Galan,
B., Harrap, S., Hamet, P., Patel, A., Neal, B.,
Woodward, M., et al (2012). Association of
HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia , 55(3),
636-643. <a href="http://dx.doi.org/10.1007/s00125-011-240
4-1">[More Information]</a>

Publications for Gregory Fulcher
Glastras, S., Fulcher, G. (2012). Guidelines for the management of gestational diabetes in pregnancy. Clinical Practice , 9(2), 161-170. <a href="http://dx.doi.org/10.2217/cpr.12.9">[More
Information]</a>
Steinbeck, K., Hazell, P., Cumming, R., Skinner,
R., Ivers, R., Booy, R., Fulcher, G., Handelsman,
D., Martin, A., Morgan, G., Starling, J., Bauman,
A., Rawsthorne, M., Chow, C., Lam, M., Kelly,
P., Paxton, K., Hawke, C., et al (2012). The study design and methodology for the ARCHER
Study - Adolescent Rural Cohort Study of
Hormones, Health, Education, Environments and
Relationships. BMC Pediatrics , 12, 1-10. <a href="http://dx.doi.org/10.1186/1471-2431-12-1
43">[More Information]</a>
2011
Scott, R., Donoghoe, M., Watts, G., O'Brien, R.,
Pardy, C., Taskinen, M., Davis, T., Colman, P.,
Manning, P., Fulcher, G., Keech, A. (2011).
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovascular Diabetology , 10(1),
102-1-102-8. <a href="http://dx.doi.org/10.1186/1475-2840-10-1
02">[More Information]</a>
Zinman, B., Fulcher, G., Rao, P., Thomas, N.,
Endahl, L., Johansen, T., Lindh, R., Lewin, A.,
Rosenstock, J., Pinget, M., et al (2011). Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet , 377(9769), 924-931.
<a href="http://dx.doi.org/10.1016/S0140-6736(10)
62305-7">[More Information]</a>
2010
Holman, R., Haffner, S., McMurray, J., Bethel,
M., Holzhauer, B., Hua, T., Belenkov, Y.,
Boolell, M., Buse, J., Buckley, B., Fulcher, G., et al (2010). Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. New
England Journal of Medicine , 362(16),
1463-1476. <a href="http://dx.doi.org/10.1056/NEJMoa100112
2">[More Information]</a>
McMurray, J., Holman, R., Haffner, S., Bethel,
M., Holzhauer, B., Hua, T., Belenkov, Y.,
Boolell, M., Buse, J., Buckley, B., Fulcher, G., et al (2010). Effect of Valsartan on the Incidence of
Diabetes and Cardiovascular Events. New
England Journal of Medicine , 362(16),
1477-1490. <a href="http://dx.doi.org/10.1056/NEJMoa100112
1">[More Information]</a>
Fulcher, G., Colagiuri, S., Phillips, P., Prins, J.,
Sinha, A., Twigg, S., Dalton, B. (2010). Insulin
Intensification for People with Type 2 Diabetes:
A Practical Approach. The Australasian Medical
Journal , 3(12), 808-813. <a href="http://dx.doi.org/10.4066/AMJ.2010.466"
>[More Information]</a>
2009
Scott, R., O'Brien, R., Fulcher, G., Pardy, C.,
D'Emden, M., Boey (Tse), D., Taskinen, M.,
Ehnholm, C., Keech, A., FIELD study investigators, F. (2009). Effects of Fenofibrate
Treatment on Cardiovascular Disease Risk in
9,795 Individuals With Type 2 Diabetes and
Various Components of the Metabolic
Syndrome: The Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD) study.
Diabetes Care , 32(3), 493-498. <a href="http://dx.doi.org/10.2337/dc08-1543">[M ore Information]</a>
2008
Tacon, L., Tan, C., Alvarado, R., Gill, A.,
Sywak, M., Fulcher, G. (2008). Drug-induced thyroiditis and papillary carcinoma in a minocycline-pigmented black thyroid gland.
Thyroid , 18(7), 795-797. <a href="http://dx.doi.org/10.1089/thy.2008.0048">
[More Information]</a>
Whitmont, K., Reid, I., Tritton, S., March, L.,
Xue, M., Lee, M., Fulcher, G., Sambrook, P.,
Slobedman, E., Cooper, A., Jackson, C. (2008).
Treatment of chronic leg ulcers with topical activated protein C. Archives of Dermatology ,
144(11), 1479-1483. <a href="http://dx.doi.org/10.1001/archderm.144.11
.1479">[More Information]</a>
2007
Niblett, S., King, K., Dunstan, H., Clifton-Bligh,
P., Hoskin, L., Roberts, T., Fulcher, G.,
McGregor, N., Dunsmore, J., Butt, H.,
Klineberg, I., et al (2007). Hematologic and
Urinary Excretion Anomalies in Patients with
Chronic Fatigue Syndrome. Experimental
Biology and Medicine , 232(8), 1041-1049.
Sponiar, M., Sharpe, L., Butow, P., Fulcher, G.
(2007). Reproductive choices of women with multiple sclerosis. International Journal of MS
Care .
2005
Chalmers, J., MacMahon, S., Colman, S., Heller,
S., Neal, B., Pan, C., Patel, A., Woodward, M.,
Cooper, M., Adams, M., Fulcher, G., Mitchell,
P., Pollock, C., Watson, J., et al (2005).
ADVANCE - Action in Diabetes and Vascular
Disease: patient recruitment and characteristics of the study population at baseline. Diabetic

Publications for Gregory Fulcher
Medicine , 22(7), 882-888.
McAvoy, B., Fulcher, G., Amerena, J., Conner,
G., Beltrame, J., Hankey, G., Keech, A., Lloyd,
B., Neale, M., Pollock, C., et al (2005). An evidence based clinical aid for cardiovascular disease--what do GPs think? Australian Family
Physician , 34(4), 297-298. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15861759">[More Information]</a>
Fulcher, G., Gilbert, R., Yue, D. (2005). Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Internal Medicine Journal , 35(9),
536-542. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16105155">[More Information]</a>
Xue, M., Thompson, P., Clifton-Bligh, R.,
Fulcher, G., Gallery, E., Jackson, C. (2005).
Leukocyte matrix metalloproteinase-9 is elevated and contributes to lymphocyte activation in type
I diabetes. The International Journal of
Biochemistry and Cell Biology , 37(11),
2406-2416. <a href="http://dx.doi.org/10.1016/j.biocel.2005.06.
003">[More Information]</a>
2004
Thomas, M., MacIsaac, R., Tsalamandris, C.,
Molyneaux, L., Goubina, I., Fulcher, G., Yue,
D., Jerums, G. (2004). Anemia In Patients With
Type 1 Diabetes. Journal of Clinical
Endocrinology and Metabolism , 89(9),
4359-4363.
Chan, S., Nery, L., McElduff, A., Wilmshurst,
E., Fulcher, G., Robinson, B., Stiel, J., Gunton,
J., Clifton-Bligh, P. (2004). Intravenous
Pamidronate In The Treatment And Prevention
Of Osteoporosis. Internal Medicine Journal ,
34(4), 162-166.
Polhill, T., Saad, S., Poronnik, P., Fulcher, G.,
Pollock, C. (2004). Short-Term Peaks In Glucose
Promote Renal Fibrogenesis Independently Of
Total Glucose Exposure. American Journal of
Physiology: Renal Physiology , 287(2),
F268-F273.
Thomas, M., MacIsaac, R., Tsalamandris, C.,
Molyneaux, L., Goubina, I., Fulcher, G., Yue,
D., Jerums, G. (2004). The Burden Of Anaemia
In Type 2 Diabetes And The Role Of
Nephropathy: A Cross-Sectional Audit.
Nephrology, Dialysis, Transplantation , 19(7),
1792-1797.
2003
Fulcher, G., Amerena, J., Conner, G., Beltrame,
J., Hankey, G., Keech, A., Lloyd, B., McAvoy,
B., Neale, M., Pollock, C., et al (2003).
Prevention of cardiovascular disease: an evidence-based clinical aid. MJA Focus , (21 July
2003), 1-14.
2001
Bernard, E., Delbridge, L., Ho, S., Roach, P.,
Fulcher, G. (2001). Superimposed double parathyroid adenoma on tc-99m mibi imaging the value of oblique images. Clinical Nuclear
Medicine , 26, 876-877.
Clifton-Bligh, P., Baber, R., Fulcher, G., Nery,,
M., Moreton, T. (2001). The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause , 8, 259-265.
2000
Hoskin (Wilson), L., Bligh, P., Hansen, R.,
Fulcher, G., Gates,, F. (2000). Bone Density and
Body Composition in Young Women with
Chronic Fatigue Syndrome. Annals of the New
York Academy of Sciences , 904(1), 625-627.
Clifton-Bligh, P., Hoskin (Wilson), L., Fulcher,
G. (2000). Chronic fatigue syndrome and the endocrine system. Current Opinion in
Endocrinology, Diabetes and Obesity , 7(2),
102-106. <a href="http://dx.doi.org/10.1097/00060793-20000
4000-00010">[More Information]</a>
Gunton, J., McElduff, A., Sulway, M., Stiel, J.,
Kelso, I., Boyce, S., Fulcher, G., Robinson, B.,
Clifton-Bligh, P., Wilmshurst, E. (2000).
Outcome of pregnancies complicated by pre-gestational diabetes mellitus. American
Journal of Obstetrics & Gynecology , 40, 38-43.